NGNE

Neurogene Inc.

A biotechnology company that engineers gene therapies for rare, severe neurological diseases, mostly affecting children, such as Rett syndrome. Its EXACT technology acts like a built-in dial, fine-tuning how much of a therapeutic protein a cell makes to avoid the toxicity that often plagues conventional gene therapy. The company was founded in 2018 by Rachel McMinn, a biotech analyst whose older brother lives with an undiagnosed neurological condition—the personal spark behind the whole venture—and it went public in 2023 through a reverse merger.

Recent Activity

Show $

2026Q2

1 sell

ArrowMark PartnersTRIM

-182.3K shares(-34.7%)

ArrowMark PartnersTRIM

-182.3K shares(-34.7%)

2026Q1

1 sell

ArrowMark PartnersTRIM

-52.7K shares(-9.1%)

ArrowMark PartnersTRIM

-52.7K shares(-9.1%)

Loading more activity...